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Abstract
Background: Gastrointestinal stromal tumors (GISTs) and adenocarcinoma are distinct neoplasms originating from
different cell layers. Approximately 20% of patients with GIST develop other cancers.
Case presentation: We report a case of the coexistence of adenocarcinoma and gastrointestinal stromal tumor
(GIST). Gastric endoscopy showed the ulcerated tumor with bleeding along the lesser curvature of the proximal
stomach and a submucosal nodule that measured about 3 cm in diameter in the lower part of the stomach body.
Their pathological examination showed gastric cancer (poorly differentiated diffuse adenocarcinoma) and GIST
(low-risk category). Further, immunohistochemical staining for C-kit and CD34 was positive, while that for SMA and
S-100 was negative.
Conclusion: Although it is not easy to speculate on the coexistence of adenocarcinoma and GIST, pre-and post-
operative diagnoses may be essential, and such cancer development is not considered to be unusual.
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Background
In recent years, the synchronous occurrence of tumors
of different histotypes arising in the same organ has
been reported more frequently. Gastrointestinal stromal
tumors (GISTs) and adenocarcinoma are distinct neo-
plasms originating from different cell layers. Although
adenocarcinoma constitutes the most common type of
gastric tumor, the synchronous development of a GIST
is relatively rare [1-6]. Here, we present and discuss a
case of synchronous gastric cancer and GIST.
Case presentation
The patient was a 67-year-old man, who had been
admitted to the hospital due to melena and a hematocrit
level of 20.1 %. Nasogastric intubation revealed a fresh
blood clot in the stomach. Urinalysis, chest and abdom-
inal films, and liver function tests were within normal
limits, and serum creatinine was 1.2 mg/dl. Five units of
packed blood cells were transfused promptly.
Abdominal CT scan showed a well-defined, heteroge-
neous mass (3 × 4 m) which was located in the lower
part of the stomach body (Figure 1). Gastric endoscopy
showed the ulcerated tumor with bleeding along the les-
ser curvature of the proximal stomach (Figure 2) and a
submucosal nodule that measured about 3 cm in dia-
meter in the lower part of the stomach body (Figure 3).
No other metastatic lesions in other organs were found
on abdominal ultrasonography or the CT scan. High-
grade gastrointestinal bleeding persisted, necessitating
the additional transfusion of ten units of packed red
blood cells. Subsequently, the patient underwent a total
gastrectomy. During the operation, there was no other
evidence of metastatic disease in the intra-abdominal
cavity. Macroscopic examination of the total gastrect-
omy specimen showed Borrman type-2 tumor measur-
ing 5 × 6 cm and submucosal nodule measuring 3 × 4
cm in the stomach (Figure 4). On histopathological
examination, the Borrman type-2 tumor gastric tumor
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showed transmural infiltration by a poorly differentiated
diffuse adenocarcinoma (Figure 5A). There was no vas-
cular invasion and no lymph node metastasis. Further
histopathological examination of the submucosal nodule
revealed GIST of the low-risk category [14], which was
composed of cytologically bland spindle cells and
showed a low mitotic index (< 5/50HPF).
The immunohistochemistry indicated strong staining
for CD34 and C-kit, while expressions of SMA and S-
100 were negative (Figure 5B-F). These findings con-
firmed the simultaneous development of gastric cancer
and GIST. The patient was subsequently discharged
without any complications.
Discussion
The coexistence of adenocarcinoma and GIST is
uncommon, and GIST has often been detected inciden-
tally in the gastric mucosa or serosa, or, occasionally,
intramurally, at surgery [1-4]. Further, gastric tumors
are derived from various other carcinomas and a precise
pre- and post-operative diagnosis is important. However,
when the GIST is submucosal or subserosal, the gastric
mucosa may not be invaded, and endoscopic biopsies
Figure 1 An abdominal computed tomography (CT) scan
showing a heterogeneous mass (3 cm × 4 cm) located in the
lower part of the stomach body. The tumor is indicated with an
arrow.
Figure 2 Gastric endoscopy confirmed an ulcerated tumor with
bleeding along the lesser curvature of the proximal stomach.
Figure 3 Gastric endoscopy showing a submucosal nodule that
measured about 3 cm in diameter in the lower part of the
stomach body.
Figure 4 Macroscopic examination of a total gastrectomy
specimen showing Borrman type-2 tumor measuring 5 × 6 cm
(black arrow) and submucosal nodule measuring 3 × 4 cm in
the stomach (white arrow).
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can be normal. In fact, in our case, the pre-operative
biopsy fragments showed only adenocarcinoma, and the
GIST was detected only in the resected stomach. There-
fore, it may be difficult to diagnose preoperatively.
Approximately 20% of patients with GIST develop
other cancers and various hypotheses have been pro-
posed regarding the simultaneous development of GIST
and adenocarcinoma [7-9]. It is not clear whether this is
a simple incidental coexistence or the two lesions are
connected by a causal relationship. Gene mutations may
underlie tumor predisposition in patients harboring a
double neoplasia. However, at present, no data are avail-
able to support such a hypothesis.
GIST is the most common mesenchymal tumor [10],
accounting for about 0.1 to 3% of all GI tumors [11].
IHC staining, such as is for CD34, smooth muscle actin
Figure 5 Microscopic examination of the proximal tumor in the stomach demonstrating typical histological findings of
adenocarcinoma (A). In addition, histopathological examination of the submucosal nodule revealed GIST of the low-risk category, composed of
cytologically bland spindle cells with a low mitotic index (< 5) (B). Immunohistochemistry indicated strong staining for CD34 (C) and C-kit (D),
while negative results were observed for S-100 (E) and SMA (F).
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(SMA), and S100, as well as c-kit (CD117), is necessary
to make an accurate diagnosis of GIST [13]. It was
revealed that c-kit and CD34 showed diffuse, strongly
positive expressions in GIST. Rabin et al. [11] reported
that 40 to 70% of GIST’s were positive for CD34, 20 to
30% were positive for SMA, and 10% were positive for
S100 protein [12,13]. Therefore, immunostaining of
CD34, c-kit, SMA, and S100 is useful, and we could
confirm the histological diagnosis using these markers.
Accordingly, immunohistochemical as well as clinical
information may be required in order to diagnose GIST
appropriately. Although it is not easy to speculate on
the coexistence of adenocarcinoma and GIST, pre- and
post-operative diagnoses may be essential. Further the
adjuvant therapy and lymphadenectomy are important.
The refinement of risk stratification systems [14] will
increase the precision of these systems for predicting
recurrence, which may facilitate improvements in indivi-
dual disease management.
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